CAPOZIDE 50/15 Drug Patent Profile

Which patents cover Capozide 50/15, and when can generic versions of Capozide 50/15 launch?

Capozide 50/15 is a drug marketed by Apothecon and is included in one NDA.

The generic ingredient in CAPOZIDE 50/15 is captopril; hydrochlorothiazide. There are fifteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the captopril; hydrochlorothiazide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Capozide 50/15

A generic version of CAPOZIDE 50/15 was approved as captopril; hydrochlorothiazide by RISING on December 29^th, 1997.

Summary for CAPOZIDE 50/15

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	9
Clinical Trials:	1
Patent Applications:	451
DailyMed Link:	CAPOZIDE 50/15 at DailyMed

Recent Clinical Trials for CAPOZIDE 50/15

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
GlaxoSmithKline	Phase 1

See all CAPOZIDE 50/15 clinical trials

US Patents and Regulatory Information for CAPOZIDE 50/15

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apothecon	CAPOZIDE 50/15	captopril; hydrochlorothiazide	TABLET;ORAL	018709-004	Oct 12, 1984		DISCN	Yes	No

Expired US Patents for CAPOZIDE 50/15

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Apothecon	CAPOZIDE 50/15	captopril; hydrochlorothiazide	TABLET;ORAL	018709-004	Oct 12, 1984
Apothecon	CAPOZIDE 50/15	captopril; hydrochlorothiazide	TABLET;ORAL	018709-004	Oct 12, 1984

International Patents for CAPOZIDE 50/15

See the table below for patents covering CAPOZIDE 50/15 around the world.

Country	Patent Number	Title	Estimated Expiration
Ireland	782413
Belgium	848228
Greece	74445

Market Dynamics and Financial Trajectory for CAPOZIDE 50/15

Last updated: March 18, 2026

What Are the Key Market Drivers for CAPOZIDE 50/15?

CAPOZIDE 50/15 combines captopril and hydrochlorothiazide, used primarily to treat hypertension. The market for fixed-dose combination (FDC) antihypertensives has seen growing demand driven by the following factors:

• Rising Prevalence of Hypertension: Worldwide, an estimated 1.28 billion adults have hypertension, according to the World Health Organization (WHO, 2021).
• Shift Toward Fixed-Dose Combinations: FDCs improve patient adherence, reduce pill burden, and streamline therapy, fostering preference among physicians.
• Generic Competition: Multiple manufacturers have introduced generic versions, decreasing prices and increasing market access.
• Regulatory Incentives: Payers and regulators favor chronic disease management drugs with proven adherence benefits.

What Is the Current Sales Environment and Revenue Outlook?

• Estimated Global Market Size: The global antihypertensive drugs market was valued at approximately $23 billion in 2022 (Grand View Research, 2022).
• CAPOZIDE-specific Share: Data on CAPOZIDE’s individual sales are scarce; however, in the US, marketed FDCs of similar composition account for about 8% of the antihypertensive market.
• Pricing Trends: Average wholesale prices for branded CAPOZIDE range from $8 to $15 per month, with generic versions priced between $4 and $8.
• Market Penetration: As a well-established product, CAPOZIDE has stable sales in North America and Europe. Emerging markets show growth potential, especially as hypertension screening improves.

How Do Regulatory and Patent Trends Affect the Market?

• Patent Status: CAPOZIDE's patent protections largely expired in the late 2010s. Generics dominate the market.
• Regulatory Approvals: The drug is included in most major hypertension treatment guidelines, aiding ongoing prescriber preference.
• Patent Challenges: No recent patent litigations threaten exclusivity; entering generics have reduced barriers.

What Are the Key Competitive Dynamics?

Competitor Type	Market Position	Approximate Market Share (Estimated)	Price Range	Key Differentiators
Branded (e.g., Toprol, Vasotec)	Moderate to low	15-20%	$12-$20	Brand reputation, physician familiarity
Generics	High	80-85%	$4-$8	Lower price point, widespread availability

• Emerging Alternatives: Newer antihypertensive classes (e.g., ARNI, SGLT2 inhibitors) are gaining acceptance but are not directly substituting CAPOZIDE.

What Is the Financial Trajectory Forecast?

• Short-term (1-3 years): Little growth anticipated; sales stabilized due to patent expiry and generic competition.
• Medium-term (3-5 years): Growth expected in emerging markets and through formulary inclusion.
• Long-term (5+ years): Limited growth without reformulation; potential for lifecycle management through new combination variants.

Projected revenue decline at an average annual rate of 2-3% in mature markets. However, expansion into new geographies and increased adherence programs could mitigate declines.

What Are the Risks and Opportunities?

Risks:

• Intensified generic competition leading to decreased prices.
• Regulatory hurdles if new formulations are introduced.
• Market pivot toward newer antihypertensive therapies.

Opportunities:

• Development of improved fixed-dose combinations.
• Expansion into underserved markets.
• Strategic partnerships to boost branding.

Key Takeaways

• CAPOZIDE 50/15 is a mature product with stable global sales fueled by hypertension prevalence.
• Market growth is limited by generic competition, but emerging markets and adherence initiatives provide expansion avenues.
• Pricing pressures are consistent with generic drug dynamics, though brand loyalty retains a role.
• Long-term financial outlook suggests slight decline barring lifecycle extension strategies.

FAQs

1. How does the patent status influence CAPOZIDE’s market?
The patent expiration in the late 2010s allowed multiple generics, reducing price and consolidating market share among generics.

2. What are the primary markets for CAPOZIDE?
North America and Europe remain stable, with growth prospects emerging in Asia-Pacific, Latin America, and Africa.

3. How competitive is the market for antihypertensive FDCs?
It is highly competitive, with generics holding about 80-85% of sales; branded options target niche segments.

4. Are there regulatory barriers to launching new formulations?
Existing guidelines favor established therapies, but reformulations require clinical trials and approval, which can delay market entry.

5. What is the outlook for pricing pressure?
Prices are expected to continue decreasing consistent with generic market trends, though well-established brands may retain premium pricing.

---

References

1. Grand View Research. (2022). Global antihypertensive drugs market size, share & trends analysis report.
2. World Health Organization. (2021). Hypertension. https://www.who.int/news-room/fact-sheets/detail/hypertension